echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Puli's new improved drug, Memantine Hydrochloride Granules, is in full swing!

    Puli's new improved drug, Memantine Hydrochloride Granules, is in full swing!

    • Last Update: 2022-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On May 25, Zhejiang Puli Pharmaceutical submitted a clinical application for the new drug category 2 of Memantine Hydrochloride Granul.
    Memantine is a best-selling anti-dementia drug for the nervous syst.
    Currently, there are capsules, tablets, and oral liquids on the mark.
    No granules have been approved for marketing or import.
     
    Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's dement.
    According to data from Min.
    com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
     
    Figure 1: 2021 Memantine Sales Percentage in Various End Markets
    Source: Mi intranet database
     
    The terminals of public medical institutions in China are the main battlefield of Memanti.
    Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
    It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
     
    Table 1: Improved new drugs declared by Zhejiang Puli Pharmaceutical since 2020
    Source: MED0 China Drug Evaluation Database
     
    Levetiracetam granules are Puli's first improved new drug to be declared for marketi.
    At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
    In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
    Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
     
    Source: CDE official website, Minet database
    On May 25, Zhejiang Puli Pharmaceutical submitted a clinical application for the new drug category 2 of Memantine Hydrochloride Granul.
    Memantine is a best-selling anti-dementia drug for the nervous syst.
    Currently, there are capsules, tablets, and oral liquids on the mark.

    No granules have been approved for marketing or import.

     
    Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's dement.

    According to data from Min.

    com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.

     
    Figure 1: 2021 Memantine Sales Percentage in Various End Markets
    Source: Mi intranet database
     
    The terminals of public medical institutions in China are the main battlefield of Memanti.

    Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.

    It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.

     
    Table 1: Improved new drugs declared by Zhejiang Puli Pharmaceutical since 2020
    Source: MED0 China Drug Evaluation Database
     
      Levetiracetam granules are Puli's first improved new drug to be declared for marketi.

    At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.

    In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.

    Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.

     
      Source: CDE official website, Minet database
      On May 25, Zhejiang Puli Pharmaceutical submitted a clinical application for the new drug category 2 of Memantine Hydrochloride Granul.

    Memantine is a best-selling anti-dementia drug for the nervous syst.

    Currently, there are capsules, tablets, and oral liquids on the mark.

    No granules have been approved for marketing or import.

     
      Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's dement.

    According to data from Min.

    com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.

    Hospital Hospital Hospital Pharmacy Pharmacy Pharmacy
     
      Figure 1: 2021 Memantine Sales Percentage in Various End Markets
      Source: Mi intranet database
     
      The terminals of public medical institutions in China are the main battlefield of Memanti.

    Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.

    It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.

     
      Table 1: Improved new drugs declared by Zhejiang Puli Pharmaceutical since 2020
      Source: MED0 China Drug Evaluation Database
     
      Levetiracetam granules are Puli's first improved new drug to be declared for marketi.

    At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.

    In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.

    Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.

    enterprise enterprise enterprise
     
      Source: CDE official website, Minet database
     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.